Related Experiment Videos
Clinical applications of amrinone.
1Department of Anesthesiology, Yale University School of Medicine, Yale-New Haven Hospital, CT 06510.
Journal of Cardiothoracic Anesthesia
|December 1, 1989
Summary
Amrinone, a phosphodiesterase inhibitor, offers a safe alternative for managing perioperative myocardial dysfunction. It improves cardiac function without increasing heart rate, benefiting patients with heart failure during surgery.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Perioperative myocardial dysfunction poses risks for patients with heart failure.
- Existing treatments may have limitations in augmenting cardiac performance without adverse effects.
Purpose of the Study:
- To evaluate amrinone as a treatment for perioperative myocardial dysfunction.
- To assess amrinone's effects on cardiac performance and hemodynamics in surgical patients.
Main Methods:
- Amrinone, a bipyridine derivative and phosphodiesterase type-3 inhibitor, was administered.
- Hemodynamic parameters and clinical outcomes were monitored in patients undergoing surgery.
Main Results:
- Amrinone provided positive inotropic support and vasodilation.
- It augmented cardiac performance without inducing tachycardia or dysrhythmias.
- Myocardial oxygen consumption was not increased.
Conclusions:
- Amrinone is a beneficial noncatecholamine, nonglycoside alternative for perioperative myocardial dysfunction.
- Its ability to improve cardiac function without increasing heart rate offers significant advantages in surgical patients with heart failure.